Drugs / SA1211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07275918 | Nov 2025 → Mar 2027 expected | chronic hepatitis B virus infection | Suzhou Siran Biotechnology Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA1211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07275918 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of SA1211 Injection” NCT07275918 ↗ |